Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/05/2790868/0/en/Aquestive-Therapeutics-Doses-First-Patient-in-Phase-3-Pivotal-Clinical-Study-Evaluating-Pharmacokinetics-and-Pharmacodynamics-of-Anaphylm-epinephrine-Sublingual-Film.html

WARREN, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that the first patient has been dosed in its initial Phase 3 pivotal Pharmacokinetic (PK) clinical study of Anaphylm™ (epinephrine) Sublingual Film. Anaphylm is the Company’s orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis.

Read more at globenewswire.com

Related news for (AQST)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.